Compare Annaly Capital Management, Inc. (NLY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs TransMedics Group Inc — how do they compare? Annaly Capital Management, Inc. trades at $22.79 (market cap $17.12B), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: Annaly Capital Management, Inc. is far larger — about 5.6× TransMedics Group Inc's market cap, and Annaly Capital Management, Inc. pays a 13.2% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| NLY | TMDX | |
|---|---|---|
Market Cap | $17.12B | $3.06B |
Sector | Financials | Technology |
52-Week High | $24.40 | $150.42 |
52-Week Low | $20.21 | $61.99 |
Dividend Yield | 13.2% | — |
Enterprise Value | — | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Annaly Capital Management (NLY) trades at $22.72, down 0.39% for the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.751 estimate. Fundamentals show a high net income margin of 92.77% and a return on equity of 20.66%, though cash flow from operations declined to $692.91 million in 2025. Recent news includes a declared $0.75 dividend and a preferred stock redemption.
The outlook for NLY is supported by analyst consensus with a $24.33 price target and a majority buy rating, indicating potential upside. However, risks include significant investing cash outflows, high leverage with debt-to-asset ratio rising to 23.55 in 2025, and sensitivity to interest rate changes. The stock offers a high dividend yield but faces headwinds from mortgage rate volatility and tax inefficiencies for investors in taxable accounts.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
